Anthrax countermeasures get US liability protection
This article was originally published in Scrip
Executive Summary
Companies that develop and manufacture medical anthrax countermeasures will receive immunity from product liability claims through 2015 under a declaration issued by the US health and human services secretary Michael Leavitt.
You may also be interested in...
Cast Members In US FDA’s COVID-19 Vaccine Advisory Committee
There are 18 people on the committee that will issue the first recommendations on COVID-19 vaccine development and licensure. Among the experts are a University of Michigan epidemiologist who will serve as acting chairman and seven temporary voting members, two of whom required conflict-of-interest waivers.
Accelerated Approval Withdrawals Through The Years
Unlike AMAG's Makena, nearly all the products that have seen their accelerated approvals pulled have left the market quietly, our infographic shows.
Gene Therapy Approval Standards: Available Treatments Influence US FDA’s View On Durability
CBER’s Peter Marks says agency assesses the importance of durability of effect differently for a gene therapy that treats a disease that has no other available therapies versus a condition for which there are multiple approved treatments. Marks’ comments shed more light on the complete response letter for BioMarin’s hemophilia gene therapy Roctavian.
Need a specific report? 1000+ reports available
Buy Reports